Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX2J57)

Drug Name

GT103 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement factor H (CFH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trumenba	DMDHCK9	Meningitis	1D01	Approved	[3]
TT-30	DMLDSX8	Autoimmune diabetes	5A10	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04314089) Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Grid Therapeutics.
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4	The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16.